XORTX Therapeutics Inc.

XORTX Therapeutics Inc. (XRTX) priced its initial public offering on Oct 14, 2021 at $4.13 per share, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $52.2M. A.G.P. was lead-left underwriter. McCarthy Tétrault and Dorsey & Whitney advised the company and TingleMerrett and Mintz advised the underwriters.

XORTX Therapeutics Inc. is a clinical-stage biotechnology company developing therapies for progressive kidney disease linked to purine and uric acid metabolism. Its three product candidates target ADPKD, acute kidney injury caused by COVID-19 infection, and type 2 diabetic nephropathy.

Status

IPO

Ticker

XRTX

Exchange

Nasdaq Capital Market

Priced

Oct 14, 2021

IPO price

$4.13

Market cap at IPO price

$52.2M

First filed

Aug 12, 2021

Underwriters

A.G.P.

Company counsel

McCarthy Tétrault and Dorsey & Whitney

Underwriters' counsel

TingleMerrett and Mintz

Sector

Biotech & pharma

Country / state

British Columbia, Canada

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.